Home Online Features Head-to-Head Preclinical Studies of SFA-002 as a Novel Psoriasis Treatment Presented at the 2025 American Academy of Dermatology Annual Meeting
Head-to-Head Preclinical Studies of SFA-002 as a Novel Psoriasis Treatment Presented at the 2025 American Academy of Dermatology Annual Meeting
Hand-out
Press Releases
SFA Therapeutics, Inc.  
March 7, 2025

Head-to-Head Preclinical Studies of SFA-002 as a Novel Psoriasis Treatment Presented at the 2025 American Academy of Dermatology Annual Meeting

Mice dosed with SFA-002 displayed reduction in psoriasis disease severity and greater reduction in skin thickening compared to etanercept and apremilast in the in vivo modelSFA-002 reduced key inflammatory markers

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social